Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- ALTERNATIVE OUTCOME MEASURES;; CONTROLLED PHASE II/III;; MYCOPHENOLATE-MOFETIL;; RHEUMATOID-ARTHRITIS;; INTRAVENOUS;; CYCLOPHOSPHAMIDE;; INITIAL VALIDATION;; MURINE LUPUS;; LONG-TERM;; ERYTHEMATOSUS;; TRIAL;; Rheumatology (1)
- Adolescent;; Antirheumatic Agents/adverse effects/ therapeutic use;; Arthritis (1)
- Adult;; Aged;; Arthritis (1)
- Autoantibodies;; Autoimmune Diseases;; Systemic Lupus Erythematosus (1)
- Celecoxib;; Juvenile idiopathic arthritis;; NSAIDs;; Safety (1)
-
- Juvenile/ drug therapy;; Child;; Child (1)
- PROTEIN DISULFIDE-ISOMERASE;; ANTI-BETA(2)-GLYCOPROTEIN I ANTIBODIES;; HUMAN ANTIPHOSPHOLIPID ANTIBODIES;; APOLIPOPROTEIN-E RECEPTOR-2';; CELL-ADHESION MOLECULE-1;; TOLL-LIKE RECEPTOR;; BETA(2)-GLYCOPROTEIN I;; TISSUE FACTOR;; DIMERIC BETA(2)-GLYCOPROTEIN-I;; ANTICARDIOLIPIN;; ANTIBODIES;; Hematology (1)
- Preschool;; Double-Blind Method;; Female;; Humans;; Male;; Recombinant Fusion Proteins/adverse effects/ therapeutic use;; Treatment Outcome (1)
- Psoriatic/ epidemiology;; Arthritis (1)
- RHEUMATOID-ARTHRITIS;; LUPUS-ERYTHEMATOSUS;; GENE-EXPRESSION;; I;; INTERFERONS;; SCLERODERMA;; THERAPY;; DISEASE;; PATHOGENESIS;; ASSOCIATION;; ACTIVATION;; Rheumatology (1)
- Rheumatoid/ epidemiology;; Cohort Studies;; Comorbidity;; Female;; Follow-Up Studies;; Humans;; Incidence;; Lymphoma/ epidemiology;; Male;; Middle Aged;; Multivariate Analysis;; Prospective Studies;; Registries;; Skin Neoplasms/ epidemiology;; United States/epidemiology (1)
Articles 1 - 7 of 7
Full-Text Articles in Medicine and Health Sciences
Platelets Are Required For Enhanced Activation Of The Endothelium And Fibrinogen In A Mouse Thrombosis Model Of Aps, V. Proulle, R. A. Furie, G. Merrill-Skoloff, B. C. Furie, B. Furie
Platelets Are Required For Enhanced Activation Of The Endothelium And Fibrinogen In A Mouse Thrombosis Model Of Aps, V. Proulle, R. A. Furie, G. Merrill-Skoloff, B. C. Furie, B. Furie
Journal Articles
Antiphospholipid syndrome (APS) is defined by thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti-beta 2-glycoprotein-1 autoantibodies (anti-beta 2GP1) that have a direct role in the pathogenesis of thrombosis in vivo. The cellular targets of the anti-beta 2GP1autoantibody/beta 2GP1complex in vivo were studied using a laser-induced thrombosis model of APS in a live mouse and human anti-beta 2GP1 autoantibodies affinity-purified from APS patients. Cell binding of fluorescently labeled beta 2GP1 and anti-beta 2GP1 autoantibodies revealed their colocalization on the platelet thrombus but not the endothelium. Anti-beta 2GP1 autoantibodies enhanced platelet activation, monitored by calcium mobilization, and endothelial activation, …
Safety Of Celecoxib And Nonselective Nonsteroidal Anti-Inflammatory Drugs In Juvenile Idiopathic Arthritis: Results Of The Phase 4 Registry, R. E. Sobel, D. J. Lovell, H. I. Brunner, J. E. Weiss, P. W. Morris, B. S. Gottlieb, E. C. Chalom, L. K. Jung, K. B. Onel, E. H. Giannini, +6 Additional Authors
Safety Of Celecoxib And Nonselective Nonsteroidal Anti-Inflammatory Drugs In Juvenile Idiopathic Arthritis: Results Of The Phase 4 Registry, R. E. Sobel, D. J. Lovell, H. I. Brunner, J. E. Weiss, P. W. Morris, B. S. Gottlieb, E. C. Chalom, L. K. Jung, K. B. Onel, E. H. Giannini, +6 Additional Authors
Journal Articles
BACKGROUND: This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis (JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs). METHODS: Children aged >/=2 to-negative polyarthritis, persistent or extended oligoarthritis, or systemic arthritis were enrolled into this prospective, observational, multicenter standard-of-care registry. Eligible patients were newly or recently prescribed (
Cell-Bound Complement Activation Products In Systemic Lupus Erythematosus: Comparison With Anti-Double-Stranded Dna And Standard Complement Measurements, C. Putterman, R. Furie, R. Ramsey-Goldman, A. Askanase, J. Buyon, K. Kalunian, W. W. Chatham, E. Massarotti, K. Kirou, T. Dervieux, +10 Additional Authors
Cell-Bound Complement Activation Products In Systemic Lupus Erythematosus: Comparison With Anti-Double-Stranded Dna And Standard Complement Measurements, C. Putterman, R. Furie, R. Ramsey-Goldman, A. Askanase, J. Buyon, K. Kalunian, W. W. Chatham, E. Massarotti, K. Kirou, T. Dervieux, +10 Additional Authors
Journal Articles
OBJECTIVE: To compare the performance characteristics of cell-bound complement (C4d) activation products (CBCAPS) on erythrocyte (EC4d) and B cells (BC4d) with antibodies to double-stranded DNA (anti-dsDNA) and complement C3 and C4 in systemic lupus erythematosus (SLE). METHODS: The study enrolled 794 subjects consisting of 304 SLE and a control group consisting of 285 patients with other rheumatic diseases and 205 normal individuals. Anti-dsDNA and other autoantibodies were measured using solid-phase immunoassays while EC4d and BC4d were determined using flow cytometry. Complement proteins were determined using immunoturbidimetry. Disease activity in SLE was determined using a non-serological Systemic Lupus Erythematosus Disease Activity …
A Comparison Of The Malignancy Incidence Among Patients With Psoriatic Arthritis And Patients With Rheumatoid Arthritis In A Large Us Cohort, R. L. Gross, J. S. Schwartzman-Morris, M. Krathen, G. Reed, H. Chang, K. C. Saunders, M. C. Fisher, J. D. Greenberg, C. Putterman, A. Broder, +3 Additional Authors
A Comparison Of The Malignancy Incidence Among Patients With Psoriatic Arthritis And Patients With Rheumatoid Arthritis In A Large Us Cohort, R. L. Gross, J. S. Schwartzman-Morris, M. Krathen, G. Reed, H. Chang, K. C. Saunders, M. C. Fisher, J. D. Greenberg, C. Putterman, A. Broder, +3 Additional Authors
Journal Articles
OBJECTIVE: To compare the incidence rates of malignancy among patients with psoriatic arthritis (PsA) and patients with rheumatoid arthritis (RA) in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. METHODS: We analyzed 2,970 patients with PsA (7,133 patient-years of followup) and 19,260 patients with RA (53,864 patient-years of followup). Using a standardized adjudication process, we identified 40 confirmed malignancies in the patients with PsA and 307 confirmed malignancies in those with RA. Incidence rates were calculated per 100 patient-years. Incidence rate ratios were estimated, with adjustment for age, sex, disease duration, body mass index, disease activity, year of …
Efficacy And Safety Of Abatacept In Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study, R. Furie, K. Nicholls, T. T. Cheng, F. Houssiau, R. Burgos-Vargas, S. L. Chen, J. L. Hillson, S. Meadows-Shropshire, M. Kinaszczuk, J. T. Merrill
Efficacy And Safety Of Abatacept In Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study, R. Furie, K. Nicholls, T. T. Cheng, F. Houssiau, R. Burgos-Vargas, S. L. Chen, J. L. Hillson, S. Meadows-Shropshire, M. Kinaszczuk, J. T. Merrill
Journal Articles
Objective. To compare the efficacy and safety of intravenous (IV) abatacept, a selective T cell costimulation modulator, versus placebo for the treatment of active class III or IV lupus nephritis, when used on a background of mycophenolate mofetil and glucocorticoids. Methods. This was a 12-month, randomized, phase II/III, multicenter, international, double-blind study. A total of 298 patients were treated in 1 of 3 IV treatment arms: placebo, abatacept at the standard weight-tiered dose (approximating 10 mg/kg), or abatacept at 30 mg/kg for 3 months, followed by the standard weight-tiered dose (abatacept 30/10). The primary end point, time to confirmed complete …
Dose-Escalation Of Human Anti-Interferon-Alpha Receptor Monoclonal Antibody Medi-546 In Subjects With Systemic Sclerosis: A Phase 1, Multicenter, Open Label Study, A. Goldberg, T. Geppert, E. Schiopu, T. Frech, V. Hsu, R. W. Simms, S. L. Peng, Y. H. Yao, N. Elgeioushi, S. Yoo, +2 Additional Authors
Dose-Escalation Of Human Anti-Interferon-Alpha Receptor Monoclonal Antibody Medi-546 In Subjects With Systemic Sclerosis: A Phase 1, Multicenter, Open Label Study, A. Goldberg, T. Geppert, E. Schiopu, T. Frech, V. Hsu, R. W. Simms, S. L. Peng, Y. H. Yao, N. Elgeioushi, S. Yoo, +2 Additional Authors
Journal Articles
Introduction: Type I interferons (IFNs) are implicated in the pathogenesis of systemic sclerosis (SSc). MEDI-546 is an investigational human monoclonal antibody directed against the type I IFN receptor. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple intravenous doses of MEDI-546 in adults with SSc. Methods: Subjects (>= 18 years) with SSc were enrolled in an open-label, dose-escalation study to receive single (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg), or 4 weekly intravenous doses (0.3, 1.0, or 5.0 mg/kg/week) of MEDI-546. Subjects were followed for 12 weeks. Safety assessments included …
Randomized, Double-Blind, Placebo-Controlled Trial Of The Efficacy And Safety Of Rilonacept In The Treatment Of Systemic Juvenile Idiopathic Arthritis, N. T. Ilowite, K. Prather, Y. Lokhnygina, L. E. Schanberg, M. Elder, D. Milojevic, J. W. Verbsky, S. J. Spalding, B. S. Gottlieb, C. I. Sandborg, +12 Additional Authors
Randomized, Double-Blind, Placebo-Controlled Trial Of The Efficacy And Safety Of Rilonacept In The Treatment Of Systemic Juvenile Idiopathic Arthritis, N. T. Ilowite, K. Prather, Y. Lokhnygina, L. E. Schanberg, M. Elder, D. Milojevic, J. W. Verbsky, S. J. Spalding, B. S. Gottlieb, C. I. Sandborg, +12 Additional Authors
Journal Articles
OBJECTIVE: To assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial. METHODS: An initial 4-week double-blind placebo phase was incorporated into a 24-week randomized multicenter design, followed by an open-label phase. Seventy-one children who had active arthritis in >/=2 joints were randomized (1:1) to the 2 arms of the study. Patients in the rilonacept arm received rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously) beginning on day 0. Patients in the placebo arm received placebo for 4 weeks followed by a loading dose of rilonacept at week 4 followed by …